Early pregnancy loss encompasses biochemical pregnancy, embryonic demise, and missed abortion, each distinguished by specific hormonal profiles and ultrasound criteria within the NaProTECHNOLOGY surveillance model. CrMS-based cycle identification enables recognition of pregnancy at the earliest stages, allowing timely hormonal intervention when progesterone or estradiol deficits are detected.
how many pregnancies are lost before clinical recognition, is the 50 percent embryo loss claim accurate, Hertig Rock study problems and criticism, what is the real early miscarriage rate, Wilcox early pregnancy loss hCG study, chemical pregnancy how common and what causes it, is human reproduction naturally inefficient, early pregnancy loss rate cycle charting monitoring
Hilgers et al. 2004, Hilgers 2004
Cite this article
Hilgers, T. W. (2004). Chapter 58: Early Pregnancy Loss. The Medical and Surgical Practice of NaProTECHNOLOGY, 797-801.
Hilgers TW. Chapter 58: Early Pregnancy Loss. The Medical and Surgical Practice of NaProTECHNOLOGY. 2004:797-801.
Hilgers, T. W. "Chapter 58: Early Pregnancy Loss." The Medical and Surgical Practice of NaProTECHNOLOGY, 2004, pp. 797-801.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Hilgers presents a refined classification of follicular and luteal phase deficiencies grounded in the integration of CrMS mucus pattern characteristics, cycle-phase-targeted estradiol and progesterone profiles, ultrasound folliculometry, and endometrial histology, introducing terminology that links specific chart signatures to defined endocrine subtypes and treatment protocols. Follicular deficiencies -- marked by short or poor-quality mucus phases and suboptimal estradiol -- and luteal deficiencies -- marked by a post-Peak phase under nine days, premenstrual spotting, or blunted serial progesterone curves -- are treated with tailored ovulation induction, cooperative progesterone replacement, and correction of contributing systemic disorders including thyroid dysfunction, hyperprolactinemia, and insulin resistance.
Stanford JB, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
The Mucus Cycle Score, derived from the standardized CrMS daily observations, quantifies cervical mucus quality and quantity across a cycle and correlates with measured estrogen levels and fecundity rates, providing a non-invasive index of reproductive potential. Declining mucus scores are clinically actionable, directing investigation into hypoestrogenism, cervical pathology, or medication effects that reduce cycle fecundity and can be corrected before ART is considered.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Preconceptional optimization using CrMS cycle data establishes hormonal baselines, identifies correctable pathologies, and guides targeted supplementation before conception is attempted. Systematic preconceptional evaluation reduces early pregnancy loss and improves obstetric outcomes by ensuring the endocrine environment supports implantation and early embryonic development.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Unusual uterine bleeding -- including premenstrual spotting, tail-end brown bleeding, mid-cycle intermenstrual bleeding, and heavy menses -- is evaluated in NaProTECHNOLOGY through prospective CrMS charting combined with cycle-phase-targeted estradiol and serial post-Peak progesterone profiles, which typically reveal luteal phase deficiency, follicular estradiol insufficiency, or anovulation as the primary etiology. Treatment is etiology-directed and cycle-synchronized: cooperative progesterone replacement for luteal defects, follicular support or ovulation induction for follicular phase insufficiency, and fertility-sparing surgical correction for structural pathology such as endometriosis, polyps, or fibroids, without routine recourse to contraceptive suppression.